Zoetis Inc. (ZTS) News
Filter ZTS News Items
ZTS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZTS News Highlights
- For ZTS, its 30 day story count is now at 41.
- Over the past 16 days, the trend for ZTS's stories per day has been choppy and unclear. It has oscillated between 1 and 16.
- BEAT, MA and NVDA are the most mentioned tickers in articles about ZTS.
Latest ZTS News From Around the Web
Below are the latest news stories about Zoetis Inc that investors may wish to consider to help them evaluate ZTS as an investment opportunity.
3 Beaten-Down Growth Stocks With More Than 50% Upside PotentialThe key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. |
Zoetis to Participate in the Bank of America Securities 2022 Animal Health SummitPARSIPPANY, N.J., February 22, 2022--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2022 Animal Health Summit on Thursday, Feb. 24, 2022. |
Analysts Are Bullish on These Healthcare Stocks: Zoetis (ZTS), SAGE Therapeutics (SAGE)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zoetis (ZTS – Research Report), SAGE Therapeutics (SAGE – Research Report) and Crispr Therapeutics AG (CRSP – Research Report) with bullish sentiments. Zoetis (ZTS) In a report released yesterday, David Steinberg from Jefferies maintained a Buy rating on Zoetis, with a price target of $235.00. The company's shares closed last Tuesday at $197.76. According to TipRanks. |
Company News for Feb 16, 2022Companies In The News Are: MAR, ZTS, TRP, ANET. |
4 Top Stock Trades for Wednesday: NVDA, SPCE, ABNB, ZTSNvidia, Virgin Galactic, Airbnb and Zoetis were our top stock trades for Wednesday. |
Pet Speciality Drugs Market to Witness Growth Acceleration | Zoetis, Merck, BayerA2Z Market Research published new research on Global Pet Speciality Drugs covering micro level of analysis by competitors and key business segments (2022-2029). The Global Pet Speciality Drugs explores comprehensive study on various segments like opportunities, size, development, innovation, sales |
Zoetis Q4 Sales Cushioned By Higher Companion Animal Product Sales, Issues FY22 OutlookZoetis Inc (NYSE: ZTS ) has reported Q4 FY21 revenue of $2 billion , an increase of 9% Y/Y, beating the consensus of $1.93 billion. Adjusted EPS was $1.00, compared to $0.91 last year and beating the consensus of $0.96. Revenue in the U.S. segment was $1.04 billion, +9%. Sales of companion animal products increased 20%, driven by … Full story available on Benzinga.com |
Zoetis tops earnings estimates and offers upbeat revenue guidance, shares up 1.5% premarketAnimal health company Zoetis Inc.''s shares jumped 1.5% premarket Tuesday, after it beat estimates for the fourth quarter and offered upbeat revenue guidance for 2022. The company posted net income of $414 million, or 87 cents a share, for the quarter, up from $359 million, or 75 cents a share, in the year-earlier period. Adjusted per-share earnings came to $1.00, ahead of the 96 cent FactSet consensus. Revenue rose to $1.967 billion from $1.807 billion, also ahead of the $1.932 billion FactSet consensus. "We expect to continue growing revenue faster than the market in the coming year, driven by continued strength in petcare; expansion of our diagnostics portfolio internationally; and significant growth in both livestock and companion animal product sales in emerging markets, including ... |
Zoetis Inc. (ZTS) CEO Kristin Peck on Q4 2021 Results - Earnings Call TranscriptNo summary available. |
Zoetis Inc. 2022 Q4 - Results - Earnings Call PresentationNo summary available. |